The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
Open accessAbstract
The success of mRNA-based therapies depends on the availability of a safe and efficient delivery vehicle. Lipid nanoparticles have been identified as a viable option. However, there are concerns whether an acceptable tolerability profile for chronic dosing can be achieved. The efficiency and tolerability of lipid nanoparticles has been attributed to the amino lipid. Therefore, we developed a new series of amino lipids that address this concern. Clear structure-activity relationships were developed that resulted in a new amino lipid that affords efficient mRNA delivery in rodent and primate models with optimal pharmacokinetics. A 1-month toxicology evaluation in rat and non-human primate demonstrated no adverse events with the new lipid nanoparticle system. Mechanistic studies demonstrate that the improved efficiency can be attributed to increased endosomal escape. This effort has resulted in the first example of the ability to safely repeat dose mRNA-containing lipid nanoparticles in non-human primate at therapeutically relevant levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [290]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [12]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [12]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [77]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [77]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [77]
Citations
Cites
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Self-citationMaier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Cited by
Sorted by citations
Items 801–820 of 820
Ali, H., Farooq, M., Shah, U., Khan, B., & Malik, S. (2026) · Pharmacophore · doi:10.51847/4ylxcn8kfc
Jiang, K., Shao, B., Li, R., Liang, T., You, C., Wang, L., Cen, J., Tan, J., Zhang, Y., Chen, M., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.3823572
pH-Sensitive Amino Lipid-Driven Pore Formation Enables Endosomal Escape of Lipid Nanoparticles
Singh, A. P., Shibata, K., Miyazaki, Y., & Shinoda, W. (2026) · Nature Communications · doi:10.1038/s41467-026-76810-y · Cited by 1
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
“Subsequent development of biodegradable ionizable lipids reinforced the need to consider both potency and metabolism [71].”
Cusatis, L. L. D., Gregorio, M. S. D., Carbone, S., Crispino, R., Tammaro, D., & Natale, C. D. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.119076 · Cited by 1
Rezaee, M., Izadi, F., Nobaharian, S., Hassani, L., Rezaei, E., Amini, S. S., Pourfathollah, A. A., Kowsari, A., Naeimi, S., Varnamkhasti, K. K., et al. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00824-0
“As reviewed by Sabnis et al. [121], LNP components (particularly cationic lipids) can induce dose-dependent hepatotoxicity and pro-inflammatory cytokine release.”
Larsson, S., Johansson, E., & Nilsson, A. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/n105134582
Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms
Wieland, J., Jackson, P., Penrod, W., Nadauld, S., & Barrott, J. J. (2026) · Cells · doi:10.3390/cells15181647
“Among these technologies, lipid nanoparticles (LNPs) are among the most clinically mature nonviral platforms for nucleic acid delivery [72–80].”
InfluentialThe CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications
Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484
Nejadnik, H., Murray, A. M., Ardestani, P. M., Mitchell, M. J., & Mahmoudi, M. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00197
mRNA-based therapies: From molecular discovery to clinical revolution
de Oliveira, A. P., Sodré, F. M. C., Louzada-Neto, O., Zylberman, M. C., da Silva, J. R., Ferreira, L. C. D. S., & Menck, C. F. M. (2026) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2026-0026
“In vivo delivery of mRNA-encoding monoclonal antibodies demonstrated detectable protein expression as early as two hours after administration, with peak expression occurring approximately two days later (Sabnis et al. , 2018).”
Physical Basis Of pK a Shift For Ionizable Lipids In An LNP-like EnvironmentPreprint
Sharma, A., Sur, S., & Grossfield, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.07.757025
“It is believed that this structural change is also what allows LNPs neutralize and encapsulate the negatively charged mRNA (6, 11), then later deliver it to target cells (6, 11, 14).”
Cook, A., Yadav, P. K., Helmy, E. W., Vlasova, K. Y., Chang, H. Y., & Wender, P. A. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c14175
Xu, B., Wei, D., Tao, K., & Wang, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101305
“Ionizable lipids can influence endosomal escape, hepatic exposure, innate immune activation, and tolerability [44,116].”
Endosomal Escape of siRNA Polyplexes: A Molecular Dynamics Perspective on Underlying Mechanisms
Steinegger, K. M., Jiang, M., Belger, F., Link, F., Winkeljann, B., & Merkel, O. M. (2026) · Advanced Functional Materials · doi:10.1002/adfm.79075 · Cited by 2
Singh, B., Sah, A., Gautam, R., Thakur, G., Kumar, D., Jayaswal, J., & Kumar, S. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00676-0
“However, high uptake does not guarantee cytosolic delivery; endosomal escape remains formulation dependent [ 53, 54, 77].”
Nanotechnology for next-generation CAR T-Cell manufacturing
Schvartzman, M., & Ghassemi, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896088
Ionizable lipid impact on mRNA vaccine formulation properties and immunogenicity
Alsaiari, S. K., Dyett, B., Daristotle, J., Tostanoski, L. H., Yu, H., Zhai, J., Nadeef, S., Forster, T. A., Mursalova, S., Drummond, C. J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115467
Brain-informed helper lipid selection enhances intracranial mRNA delivery
Cheung, K., Williams, M. A. C., Wu, Z., Liu, D., Wang, S. X., McHugo, B., Gona, P., Li, A., Baktir, B., Rao, S., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100616
Programmable mRNA vaccine materials for temporal control of antitumour immunity
Jeong, S. D., Tang, C., Wang, X., Szeglowski, A., Kim, Y., Kim, B., Sharma, P., Moon, J. J., Jiang, W., & Kim, B. Y. S. (2026) · Nature Reviews Materials · doi:10.1038/s41578-026-00974-8
Metadata
- Authors
- Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., Almarsson, Ö., Stanton, M. G., & Benenato, K. E.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Benenato, Kerry E.
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 26
- Issue
- 6
- Pages
- 1509-1519
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC5986714
- OpenAlex
- W2791854174
- Cited by
- 820
- References
- 20
- Citations by year
- 2026: 107 · 2025: 139 · 2024: 156 · 2023: 139 · 2022: 116 · 2021: 73 · 2020: 51 · 2019: 31 · 2018: 7
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- mRNA delivery, lipid nanoparticles, endosomal escape, structure-activity relationship, pharmacokinetics, toxicology, non-human primates
- MeSH terms
- Animals, Lipids, Primates, RNA, Messenger, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
